Blue Fin Group, a life sciences strategy consulting firm, proudly announces the recent addition of several associates to our firm. Each of these new hires is strongly grounded in the life sciences industry and demonstrates track records of ongoing success. They bring detailed commercialization experience to the firm and excel in areas of thought leadership such as payer experience, pricing, and specialty pharmacy, and have the highest accolades from prior clients and contacts.
Erynn Wardwell, Principal Consultant – Joining us from Jupiter Life Sciences, Erynn has key experience in the payer and market access strategy, pricing and reimbursement strategy, access and affordability optimization, and product launch. Having worked for manufacturers and with a deep career in consulting, Erynn has helped develop commercial strategies ranging from top-selling drugs to novel agents indicated for orphan diseases. Erynn has consulted with clients across a wide variety of therapeutic areas, including oncology, diabetes, infectious diseases, women’s health, opioid overdose, and ophthalmology to advise companies on pricing and market access strategies.
Cheryl Allen, Principal Consultant – Joining us from her recent position as VP, Business Development at Diplomat Specialty Pharmacy, Cheryl’s broad and deep experience in the patient journey will augment our firm’s efforts in many areas of significance to Blue Fin Group clients. She brings an important mix of experience in entrepreneurial and corporate initiatives, having served as the beacon of both Specialty Pharmaceuticals and Specialty Pharmacy during their inaugural years. A trained pharmacist with her Master’s in Business, Cheryl approaches the topic of pharmacy with a strong head for the pharmacoeconomic journey from the perspective of the payer, patient reimbursement, access and affordability.
Nicholas Stephens, Senior Consultant – Joining us from the consulting division of IQVia, Nick is skilled at helping manufacturers navigate complex global access and reimbursement landscapes and optimize their strategies to communicate the value of their innovation to patients, providers, and payers. In his experience as a lawyer and working for PhRMA on international commercialization topics, Nick has advised clients on brand, commercial, pricing, and market access strategies for primary and specialty care products, ranging from small molecules, to biologics, to cell and gene therapies.
Brent Knoblauch, Consultant – Joining us from Navigant consulting, Brent is skilled in clinical science and business, providing clients with actionable insights and strategies to optimize the Pharmacoeconomics for all stakeholders. Brent has been an entrepreneur since he started his career working for Intermountain Health in Cell and Gene Therapies, start-ups and private equity. He has a strong background in market access and reimbursement strategy across the pharmaceutical, diagnostic, and device industries, and has a strong passion for the advancement of product-based healthcare.
Please join us in welcoming them to Blue Fin Group and stay tuned for future updates on our firm’s staffing and other relevant developments. More information on all our associates, including the above, can be found at consultbfg.com, and we can be reached via email directly from our profiles on the site.
For more information on current opportunities at Blue Fin Group, contact Megan Miller.
Blue Fin Group is a life sciences strategy consulting firm. Since our founding in 2001, our integrated team of subject-matter experts has become well-known for creating unique insights, our broad and deep knowledge of the healthcare ecosystem, and a trusted methodology to deliver consistent performance across a broad spectrum of commercialization capabilities.
Connect with us to learn how our experts can assist with your business challenges. www.consultbfg.com